Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PD-L1 Antibody”

371 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 371 results

Testing effectiveness (Phase 2)Study completedNCT04177810
What this trial is testing

Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer

Who this might be right for
Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 25
Large-scale testing (Phase 3)Study completedNCT04102098
What this trial is testing

Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation

Who this might be right for
Carcinoma, Hepatocellular
Hoffmann-La Roche 668
Testing effectiveness (Phase 2)Ended earlyNCT05159388
What this trial is testing

PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody) in Patients With Solid Tumors

Who this might be right for
Solid Tumor
Servier Bio-Innovation LLC 46
Not applicableLooking for participantsNCT05713994
What this trial is testing

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma Non-resectable
Ze-yang Ding, MD 300
Early research (Phase 1)Study completedNCT01656642
What this trial is testing

A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma

Who this might be right for
Malignant Melanoma
Genentech, Inc. 67
Testing effectiveness (Phase 2)Ended earlyNCT02938793
What this trial is testing

Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors

Who this might be right for
CancerRare Disease
Prisma Health-Upstate 92
Large-scale testing (Phase 3)Active Not RecruitingNCT03271372
What this trial is testing

Adjuvant Avelumab in Merkel Cell Cancer

Who this might be right for
Stage III Merkel Cell Carcinoma AJCC v8Stage IIIB Merkel Cell Carcinoma AJCC v8Stage IIIA Merkel Cell Carcinoma AJCC v8
University of Washington 101
Testing effectiveness (Phase 2)Study completedNCT04393753
What this trial is testing

Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1

Who this might be right for
Merkel Cell Carcinoma
4SC AG 19
Large-scale testing (Phase 3)Study completedNCT03134872
What this trial is testing

SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC

Who this might be right for
Lung NeoplasmsCarcinoma, Non-Small-Cell LungRespiratory Tract Neoplasms+6 more
Jiangsu HengRui Medicine Co., Ltd. 419
Large-scale testing (Phase 3)Study completedNCT04878016
What this trial is testing

Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-PD-L1 Antibody) in Patients With ES-SCLC

Who this might be right for
Extensive-stage Small-cell Lung Cancer
Lee's Pharmaceutical Limited 498
Testing effectiveness (Phase 2)Looking for participantsNCT06827236
What this trial is testing

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

Who this might be right for
Locally Advanced Breast CancerUnresectable Breast CarcinomaMetastatic Breast Cancer
BioNTech SE 380
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06946836
What this trial is testing

Comparison of Neoadjuvant Cadonilimab Versus Chemotherapy Combined With PD-1 in the Treatment of Resectable Non-Small Cell Lung Cancer With High PD-L1 Expression: A Single-Center, Randomized, Exploratory Clinical Study

Who this might be right for
Resectable Non-small Cell Lung CancerBispecific AntibodyNeoadjuvant Therapy
Shanghai Pulmonary Hospital, Shanghai, China 80
Early research (Phase 1)Looking for participantsNCT05410717
What this trial is testing

CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors

Who this might be right for
Stage IV Ovarian CancerTestis Cancer, RefractoryEndometrial Cancer Recurrent+1 more
Second Affiliated Hospital of Guangzhou Medical University 200
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07358585
What this trial is testing

A Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastatic Colorectal Cancer

Who this might be right for
Colon Cancer Adenocarcinoma
Shanghai Henlius Biotech 126
Not applicableLooking for participantsNCT07291063
What this trial is testing

Anti-PD-1/PD-L1 Antibodies Plus Gemcitabine and Cisplatin for Advanced CCA

Who this might be right for
Cholangiocarcinoma
Shanghai Zhongshan Hospital 50
Early research (Phase 1)Study completedNCT02261220
What this trial is testing

MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
MedImmune LLC 380
Testing effectiveness (Phase 2)Looking for participantsNCT06978114
What this trial is testing

BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer

Who this might be right for
Advanced Biliary Tract Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 46
Testing effectiveness (Phase 2)UnknownNCT04215471
What this trial is testing

NeoAdjuvant Therapy With Immunoreagent (SHR-1316) for Resectable Oesophageal Squamous Cell carciNoma

Who this might be right for
Oesophageal Squamous Cell Carcinoma
Shanghai Zhongshan Hospital 30
Testing effectiveness (Phase 2)Study completedNCT06029127
What this trial is testing

Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
BeiGene 35
Testing effectiveness (Phase 2)Study completedNCT04122625
What this trial is testing

Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143

Who this might be right for
Solid Tumor
Debiopharm International SA 46
Next Page